Proteomic Profiling of BRAFV600E Mutant Colon Cancer Cells Reveals the Involvement of Nucleophosmin/c-Myc Axis in Modulating the Response and Resistance to BRAF Inhibition by Vemurafenib

BRAFV600E mutations are found in approximately 10% of colorectal cancer patients and are associated with worse prognosis and poor outcomes with systemic therapies. The aim of this study was to identify novel druggable features of BRAFV600E-mutated colon cancer (CC) cells associated with the response...

Descripción completa

Detalles Bibliográficos
Autores principales: Grbčić, Petra, Fučkar Čupić, Dora, Gamberi, Tania, Kraljević Pavelić, Sandra, Sedić, Mirela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8228139/
https://www.ncbi.nlm.nih.gov/pubmed/34201061
http://dx.doi.org/10.3390/ijms22126174

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8228139/
https://www.ncbi.nlm.nih.gov/pubmed/34201061
http://dx.doi.org/10.3390/ijms22126174

Ejemplares similares